REG - Avacta Group PLC - Completion of Dose Escalation and RDE Arms

AvactaAnnouncement

12/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241212:nRSL7701Pa&default-theme=true

RNS Number : 7701P  Avacta Group PLC  12 December 2024

 

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

 

Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000
Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open
for Enrolment

 

 

LONDON - Dec. 12, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences
company developing next generation peptide drug conjugates (PDC) targeting
powerful anti-tumor payloads directly to the tumor, today announces the
completion of the enrollment in the AVA6000 Phase 1a Dose Escalation and
Recommended Dose for Expansion (RDE) cohort, and the opening of the Phase 1b
disease-specific expansion cohorts in the trial. Patient screening has
commenced.

 

The Phase 1b expansion cohorts follow the encouraging preliminary results in
the trial reported earlier in 2024 demonstrating a favorable safety profile
and significant antitumor activity in patients with salivary gland cancers (a
subset of head and neck cancer) and high-grade soft tissue sarcoma.

 

The Phase 1b cohorts will enroll patients in three disease-specific cohorts
including: (1) triple negative breast cancer; (2) salivary gland cancer and
(3) high grade soft tissue sarcoma.

 

Updated data for the Phase 1 dose escalation cohorts and the recommended dose
for expansion cohort will be presented in the first half of 2025.

 

Christina Coughlin, MD PhD, CEO of Avacta, commented: "We are encouraged by
the anti-tumor activity observed in the Phase 1 dose escalation and RDE
cohorts of the trial and the expansion cohorts are designed to build on that
knowledge.  Opening of the expansion cohorts represents a significant
milestone in the development of FAP-Doxorubicin (AVA6000) in that we will now
be able to assess the activity in specific indications to better plan Phase 2
development."

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc

 Michael Vinegrad, Group Communications Director       https://avacta.com/ (https://avacta.com/)
 Peel Hunt (Nomad and Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden / Patrick Birkholm
 ICR Healthcare                                        avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

About AVA6000: FAP-enabled doxorubicin

The lead pre|CISION(®) program AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple patients.To register for
news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

About Avacta Group plc - https://avacta.com/ (https://avacta.com/)

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics. Its
clinical stage oncology biotech division Avacta Therapeutics is harnessing the
proprietary pre|CISION(®) platform technology to develop novel, highly
targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare
professionals and broadening access to diagnostics. To register for news
alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGQGPUPCPGG